Ontology highlight
ABSTRACT:
SUBMITTER: Hata AN
PROVIDER: S-EPMC5700857 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
Hata A N AN Rowley S S Archibald H L HL Gomez-Caraballo M M Siddiqui F M FM Ji F F Jung J J Light M M Lee J S JS Debussche L L Sidhu S S Sadreyev R I RI Watters J J Engelman J A JA
Oncogene 20170807 47
There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2 inhibitors as a potential treatment strategy for KRAS mutant non-small cell lung cancers (NSCLC) and colorectal carcinomas that harbor wild-type TP53. The combination of pimasertib (MEK inhibitor) and SAR405838 (MDM2 inhibitor) was synergistic and i ...[more]